152 related articles for article (PubMed ID: 29452241)
1. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing.
Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Rome S; Schubert MA; Aerts L; De Beer T
Eur J Pharm Biopharm; 2018 Jun; 127():92-103. PubMed ID: 29452241
[TBL] [Abstract][Full Text] [Related]
2. A Commentary on Co-Processed API as a Promising Approach to Improve Sustainability for the Pharmaceutical Industry.
Schenck L; Risteen B; Johnson LM; Koynov A; Bonaga L; Orr R; Hancock B
J Pharm Sci; 2024 Feb; 113(2):306-313. PubMed ID: 38065243
[TBL] [Abstract][Full Text] [Related]
3. Ten years of the manufacturing classification system: a review of literature applications and an extension of the framework to continuous manufacture.
Leane M; Pitt K; Reynolds G; Tantuccio A; Moreton C; Crean A; Kleinebudde P; Carlin B; Gamble J; Gamlen M; Stone E; Kuentz M; Gururajan B; Khimyak YZ; Van Snick B; Andersen S; Misic Z; Peter S; Sheehan S
Pharm Dev Technol; 2024 Jun; 29(5):395-414. PubMed ID: 38618690
[TBL] [Abstract][Full Text] [Related]
4. Current Trends in API Co-Processing: Spherical Crystallization and Co-Precipitation Techniques.
Dhondale MR; Nambiar AG; Singh M; Mali AR; Agrawal AK; Shastri NR; Kumar P; Kumar D
J Pharm Sci; 2023 Aug; 112(8):2010-2028. PubMed ID: 36780986
[TBL] [Abstract][Full Text] [Related]
5. A framework for the in silico assessment of the robustness of an MPC in a CDC line in function of process variability.
Waeytens R; Van Hauwermeiren D; Grymonpré W; Nopens I; De Beer T
Int J Pharm; 2024 Jun; 658():124137. PubMed ID: 38670472
[TBL] [Abstract][Full Text] [Related]
6. A Rational Hierarchy to Capture Raw Material Attribute Variability in the Pharmaceutical Drug Product Development and Manufacturing Lifecycle.
Conway SL; Rosenberg KJ; Sotthivirat S; Goldfarb DJ
J Pharm Sci; 2024 Mar; 113(3):523-538. PubMed ID: 37838275
[TBL] [Abstract][Full Text] [Related]
7. Design Space Identification and Visualization for Continuous Pharmaceutical Manufacturing.
Diab S; Gerogiorgis DI
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32151096
[TBL] [Abstract][Full Text] [Related]
8. Quality by Design Considerations for Drop-on-Demand Point-of-Care Pharmaceutical Manufacturing of Precision Medicine.
Forbes TP; Gillen JG; Feeney W; Ho J
Mol Pharm; 2024 Jul; 21(7):3268-3280. PubMed ID: 38661480
[TBL] [Abstract][Full Text] [Related]
9. Analytical comparison between batch and continuous direct compression processes for pharmaceutical manufacturing using an innovative UV-Vis reflectance method and chemometrics.
Macchietti L; Melucci D; Menarini L; Consoli F; Zappi A
Int J Pharm; 2024 May; 656():124090. PubMed ID: 38582101
[TBL] [Abstract][Full Text] [Related]
10. End-to-end continuous manufacturing of conventional compressed tablets: From flow synthesis to tableting through integrated crystallization and filtration.
Domokos A; Nagy B; Gyürkés M; Farkas A; Tacsi K; Pataki H; Liu YC; Balogh A; Firth P; Szilágyi B; Marosi G; Nagy ZK; Nagy ZK
Int J Pharm; 2020 May; 581():119297. PubMed ID: 32243964
[TBL] [Abstract][Full Text] [Related]
11. Batch vs. continuous direct compression - a comparison of material processability and final tablet quality.
Bekaert B; Janssen PHM; Fathollahi S; Vanderroost D; Roelofs T; Dickhoff BHJ; Vervaet C; Vanhoorne V
Int J Pharm X; 2024 Jun; 7():100226. PubMed ID: 38235316
[TBL] [Abstract][Full Text] [Related]
12. Templated Reactive Crystallization of Active Pharmaceutical Ingredient in Hydrogel Microparticles Enabling Robust Drug Product Processing.
Manghnani PN; Schenck L; Khan SA; Doyle PS
J Pharm Sci; 2023 Aug; 112(8):2115-2123. PubMed ID: 37160228
[TBL] [Abstract][Full Text] [Related]
13. Impact of active pharmaceutical ingredient variables and oleaginous base on the in vitro drug release from ophthalmic ointments: An investigation using dexamethasone as a model drug.
Mekjaruskul C; O'Reilly Beringhs A; Qin B; Wang Y; Lu X
Int J Pharm; 2024 Jun; 658():124184. PubMed ID: 38692497
[TBL] [Abstract][Full Text] [Related]
14. Generic dry powder inhalers bioequivalence: Batch-to-batch variability insights.
Salama R; Choi HJ; Almazi J; Traini D; Young P
Drug Discov Today; 2022 Nov; 27(11):103350. PubMed ID: 36096359
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Drug Development: Harnessing the Sustainability of Pharmaceutical Cocrystals.
Aitipamula S; Bolla G
Mol Pharm; 2024 Jul; 21(7):3121-3143. PubMed ID: 38814314
[TBL] [Abstract][Full Text] [Related]
16. A strategic approach towards mass balance investigations in pharmaceutical drug substance release testing: A peculiar out of specification case study encountered during API manufacture.
Scott BS; Zhang K; Yehl PM; Yang SH
J Pharm Biomed Anal; 2024 Jan; 238():115773. PubMed ID: 37866077
[TBL] [Abstract][Full Text] [Related]
17. Accelerating Process Development and Product Formulation.
Futran M; Muzzio F; Chatterjee B
Pharm Res; 2024 May; 41(5):833-837. PubMed ID: 38698195
[TBL] [Abstract][Full Text] [Related]
18. Brazilian national production of active pharmaceutical ingredients: regulatory and strategic framework.
Tonini MDL; Lopes RO; Barbosa MLC
An Acad Bras Cienc; 2023; 95(suppl 2):e20230321. PubMed ID: 38126436
[TBL] [Abstract][Full Text] [Related]
19. Scalability of Pharmaceutical Co-Crystal Formation by Mechanochemistry in Batch.
Bodach A; Portet A; Winkelmann F; Herrmann B; Gallou F; Ponnusamy E; Virieux D; Colacino E; Felderhoff M
ChemSusChem; 2024 Mar; 17(6):e202301220. PubMed ID: 37975728
[TBL] [Abstract][Full Text] [Related]
20. Process analytical technology in Downstream-Processing of Drug Substances- A review.
Neugebauer P; Zettl M; Moser D; Poms J; Kuchler L; Sacher S
Int J Pharm; 2024 Jul; ():124412. PubMed ID: 38960339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
